Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Seneca House Advisors

Seneca House Advisors boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,174 shares of the medical research company’s stock after purchasing an additional 595 shares during the quarter. Thermo Fisher Scientific comprises 2.1% of Seneca House Advisors’ portfolio, making the stock its 17th largest position. Seneca House Advisors’ holdings in Thermo Fisher Scientific were worth $5,293,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Apeiron RIA LLC increased its holdings in shares of Thermo Fisher Scientific by 22.3% during the 4th quarter. Apeiron RIA LLC now owns 939 shares of the medical research company’s stock worth $489,000 after buying an additional 171 shares during the last quarter. Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $30,000. D.B. Root & Company LLC grew its holdings in shares of Thermo Fisher Scientific by 39.2% during the 4th quarter. D.B. Root & Company LLC now owns 920 shares of the medical research company’s stock worth $479,000 after purchasing an additional 259 shares during the period. Echo45 Advisors LLC increased its position in Thermo Fisher Scientific by 6.1% during the 4th quarter. Echo45 Advisors LLC now owns 573 shares of the medical research company’s stock worth $305,000 after purchasing an additional 33 shares in the last quarter. Finally, True North Advisors LLC lifted its position in Thermo Fisher Scientific by 9.7% during the fourth quarter. True North Advisors LLC now owns 624 shares of the medical research company’s stock valued at $325,000 after buying an additional 55 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 44,850 shares of company stock valued at $24,666,097 over the last three months. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.0 %

Shares of TMO stock opened at $574.83 on Friday. The business’s fifty day moving average is $531.52 and its 200-day moving average is $569.01. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The stock has a market cap of $219.87 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the company earned $5.69 EPS. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Bernstein Bank raised their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, Morgan Stanley dropped their price target on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.